Also considered
13 papers judged, 2 emailed · Read the digest →
NCCN guidelines update for pancreatic adenocarcinoma, published in JNCCN, covering workup, staging, and treatment from resectable to metastatic disease. Provides the current standard-of-care framework for managing pancreatic cancer.
NCCN Guidelines Insights for hepatocellular carcinoma (version 2.2026), published in JNCCN, highlighting recent updates to recommendations. Directly informs current evaluation and systemic treatment practice for HCC.
ASCO living guideline on liquid biopsy and systemic treatment of advanced biliary tract cancer, published in JCO. Recommends broad NGS testing, ICI plus chemotherapy first-line, and biomarker-directed later-line options, guiding practice.
Propensity-matched observational cohort of patients with recurrent pancreatic cancer after resection, published in European Journal of Cancer. Recurrence-focused treatment was associated with longer post-recurrence survival than supportive care alone, with prognosis-based subgroup analysis to guide treatment selection.
Systematic review of clinical trials of therapeutic cancer vaccines in pancreatic ductal adenocarcinoma, published in Lancet Gastroenterology & Hepatology. Early-phase studies show feasibility and immunogenicity but rarely durable clinical benefit, so vaccines remain investigational, with personalised neoantigen mRNA approaches the most promising.
Single-arm phase 2 basket trial (TAPUR) in advanced BRAF V600E-mutant thyroid and biliary tract cancers, published in JCO Precision Oncology. Cobimetinib plus vemurafenib showed encouraging disease control and responses, supporting BRAF/MEK targeting in these refractory, biomarker-selected patients.
Single-arm phase 2 trial in localized dMMR/MSI-H gastric/GEJ adenocarcinoma, published in JAMA Oncology, reporting long-term event-free and overall survival after neoadjuvant nivolumab plus ipilimumab. Supports durable benefit of this chemotherapy-free approach in a biomarker-selected population.
Multicenter single-arm phase 2 in untreated metastatic pancreatic adenocarcinoma, published in Clinical Cancer Research. Adding PD-1 blockade and radiotherapy to gemcitabine/nab-paclitaxel was tolerable and showed encouraging activity with exploratory ctDNA and microenvironment biomarkers, but needs randomized confirmation.
Commentary in Cancer Cell on an early-phase trial combining an intravenous KRAS G12D inhibitor with a PD-L1 inhibitor in previously treated metastatic pancreatic cancer. It highlights a promising response rate and a favorable GI tolerability profile, but remains early-phase and hypothesis-generating.
Retrospective SEER-Medicare cohort of older long-term survivors of breast, prostate, colon and rectal cancer, published in J Natl Cancer Inst. Describes late second primary cancer patterns to inform survivorship surveillance, without changing systemic treatment choices.
Retrospective registry cohort in resected stage I-III grade 3 gastroenteropancreatic neuroendocrine carcinoma, published in European Journal of Cancer. Suggests perioperative chemotherapy is associated with better event-free and recurrence-free survival, possibly by lowering residual disease burden, but not clearly overall survival.
Large retrospective clinicogenomic cohort analysis of cancer cachexia episodes, published in Nature Medicine. Links cachectic weight loss to progression, outcomes and tumor genotypes and offers a validated risk prediction model in lung, colorectal and prostate cancer, but does not directly guide systemic therapy choices.
Unplanned post hoc cohort analysis of two German phase 2 trials of total neoadjuvant therapy in locally advanced rectal cancer, published in JAMA Network Open. Informs counseling on quality of life and function with organ preservation (watch-and-wait) versus total mesorectal excision.